key: cord-0853087-4ya2salo
authors: Williams, Austin D.; Bleicher, Richard J.
title: ASO Author Reflections: Neoadjuvant Endocrine Therapy: A Pill in Time Saves Nine
date: 2022-01-06
journal: Ann Surg Oncol
DOI: 10.1245/s10434-021-11145-0
sha: c8d65758b06adc1897c8f985bb859298358f66e5
doc_id: 853087
cord_uid: 4ya2salo

nan

The incidence of ductal carcinoma in situ (DCIS) has increased since screening mammography has become more widespread, leading to many more surgical excisions for non-invasive disease. 1 However, the identification and treatment of pre-invasive disease has not decreased the rate of invasive or advanced breast cancers diagnosed over the same time period. This, and the degree of complexity related to the transformation of DCIS to invasive ductal carcinoma (IDC), have led to the development of ongoing trials investigating whether endocrine therapy and surveillance is a safe alternative to surgical excision in hormone receptor-positive (HR?) DCIS. 2 Additionally, the postponement of many elective surgeries during the initial wave of the coronavirus disease 2019 (COVID-19) pandemic provided an impetus to implement an underused strategy of neoadjuvant endocrine therapy (NET) in HR? DCIS and IDC as a bridge to surgery. 3 Our group previously demonstrated a higher upgrade rate from DCIS to IDC in longer surgical delays, 4 therefore we were interested in whether NET modulates this difference.

Given that the data from the trials of nonoperative management and post-pandemic outcomes are not yet available, the impact of NET and its interaction with surgical delay in patients with HR? DCIS remains unknown. We sought to investigate whether there is an interaction between surgical delay and the use of NET in HR? DCIS in a prepandemic cohort, in order to determine whether NET limits progression to IDC. 5 As expected, only a small proportion (0.3%) of patients in this cohort received NET, and its use and duration were not associated with upgrade to IDC when examined on univariate and multivariable analyses. However, we did find evidence of a potential protective effect when stratifying by surgical delay, where the rate of upgrade increased for patients who did not receive NET, but did not increase in patients who received NET.

NET was uncommonly used in patients with DCIS prior to the pandemic, and we still cannot distinguish between DCIS that will remain indolent and that which becomes invasive. But if NET limits progression, as our study suggests, it may help combat the latter. With larger numbers of patients in contemporary prospective cohorts, it will be important to investigate the onset of action of NET, the magnitude and durability of the protective effect, and whether progression to invasion can be partly or even completely controlled. Such a capability would truly turn DCIS into a risk factor, and add new meaning to the expression 'an ounce of prevention is worth a pound of cure'.

Effect of three decades of screening mammography on breast-cancer incidence

The international collaboration of active surveillance trials for low-risk DCIS

Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. The COVID-19 pandemic breast cancer consortium

Preoperative delays in the treatment of DCIS and the Associated Incidence of Invasive Breast Cancer

Neoadjuvant endocrine therapy and delays in surgery for ductal carcinoma in situ: implications for the coronavirus pandemic